Human induced pluripotent stem cells (iPSCs) share many properties with embryonic stem cells (ESCs), including self-renewal, pluripotency and a theoretically unlimited supply. Several reasons have made iPSCs derived from patients the system of choice, including the fact that the use of human ESCs presents significant ethical concerns due to the use of human embryos. One of the most promising advantages of iPSCs is their use in creating patient-specific disease models derived from an individual's own fibroblasts [1-2]. Such models offer the possibility of gaining a deeper understanding of disease mechanisms, but can also be useful for drug screening and personalized medicine [3-4]. Over the last ten years, numerous studies have utilized iPSC-derived neurons to explore mechanisms of neurodegenerative disorders such as Parkinson's disease (PD), Alzheimer's disease (AD) and Amyotrophic lateral sclerosis (ALS) [5]. However, these approaches are still limited, particularly for cultures that model neurological or psychiatric disorders and require resolution of individual neurons or defined networks, both of which are challenging because cells tend to form dense clusters during the differentiation process. Several approaches are in development to address
